The benefit of adjuvant neratinib is generally proportional to the residual risk of recurrence following definitive therapy including HER-targeted adjuvant therapy. In the ExteNET study final efficacy report, the absolute difference in overall survival at 5 years was estimated at 9.1% in 295 patient...